Herbal Products Review Provides Inaccurate Information on Dietary Supplement Regulations  by Chaudhry, M. Hafeez
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September 7, 2010:903–9Although the investigators presented important information
e.g., that St. John’s Wort extracts and grapefruit juice affect the
etabolism of many drugs used by cardiologists), the bulk of the
eport appears to be a collection of medical database “hits”;
ne-third of the herbs identified are rarely or never present in the
.S. marketplace. The investigators also stray from their central
urpose by opining on diverse topics outside the scope of their
xpertise, such as quality control, advertising, and basic dietary
upplement regulation.
Reported problems regarding botanicals include, for example,
hat “colchicine has been found in the placenta of women taking
inkgo” (1), an erroneous finding that has been soundly discredited
3–5). Similarly, in their discussion of ginseng, the investigators
tate that “neonatal death has been related to maternal use” (1).
owever, the material consumed in this case of neonatal androg-
nization (not death) was reported in the cited reference as not a
rue ginseng, not “Siberian ginseng” (as stated in the original
eport), but confirmed by Canadian government researchers as
hinese silk vine (6,7).
Additionally, although the investigators claim in an unrefer-
nced statement that products made from the herb black cohosh
inhibit CYP3A4 and potentially increase the risk of adverse effects
rom some drugs” (1), the fact is that although 1 in vitro study
ndicated this possibility, 3 others, including 2 human studies, have
onfirmed that no such inhibition is associated with this herb
8–10).
Clinically significant information about how herbs affect drug
etabolism, particularly patients on digoxin or warfarin, is impor-
ant to cardiologists. However, the investigators do not provide
eferences for dozens of their assertions in this area, and they get
he facts wrong in several places in which they do provide
eferences.
Although the investigators’ intent is appreciated, it is important
hat the review and dissemination of safety information on herbs
e held to the same standards found in any other field of scientific
ndeavor (11). In the interest of patient safety and provider
ducation, the American Herbal Products Association published
he Botanical Safety Handbook in 1997 (12). A thoroughly revised
dition will be available in the near future, with the hope that it
ill be recognized as a valuable tool for credible and up-to-date
nformation on the safety of herbs.
Steven Dentali, PhD
American Herbal Products Association
630 Fenton Street, Suite 918
ilver Spring, Maryland 20910
-mail: sdentali@ahpa.org
doi:10.1016/j.jacc.2010.03.074
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erbal Products Review
rovides Inaccurate Information
n Dietary Supplement Regulations
achjian et al. (1) fail to present a meaningful review of the
hallenges of herbal supplement use in patients with cardiovascular
isease. Instead, they present outdated and incorrect information
nd make sweeping generalizations about herbal products and
ietary supplements in general. As a result, the reader is no better
quipped to manage patient care. This is unfortunate, because the
otential for drug–herb interactions is a critical topic and is
linically relevant for practicing cardiologists, as 24% of consumers
ave reported using herbal supplements (2), with few patients
iscussing this supplementation with their health care profession-
ls. Those patients willing to discuss herbal use with their
hysicians often project distrust of medicine when natural products
re too eagerly dismissed.
One apparent purpose of the review was to highlight what are
erceived by the investigators as regulatory shortfalls of the dietary
upplement industry. However, they lack a fundamental under-
tanding of the regulatory requirements. Herbal supplements are
onsidered dietary supplements as defined in the Dietary Supple-
ent Health and Education Act of 1994 (DSHEA) (3), which
rovides a regulatory framework distinct from that for conven-
ional foods or drugs. In their review, the investigators make
umerous references to products that are not herbal dietary
upplements or are not commonly available. It is unclear, for
xample, why a review on herbal supplements would highlight drug
nteractions with grapefruit juice, a food. In claiming a lack of
overnment oversight, the investigators state that “the only require-
ent is for the manufacturer to send a copy of the product label to the
.S. Food and Drug Administration (FDA)” (1). Although there are
umerous requirements in place for herbal dietary supplements,
ubmitting a label to the FDA is not among them. The investigators
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905JACC Vol. 56, No. 11, 2010 Correspondence
September 7, 2010:903–9ontinue, “A new dietary supplement . . . can be introduced and
arketed overnight . . . despite containing new, experimental, and
nregulated herbal ingredients” (1). Again, this statement is false.
f a manufacturer wishes to market a product that contains a new
erbal ingredient, there is a new dietary ingredient 75-day pre-
arket notification process in which safety data are supplied to the
DA for review (4). Similarly, the investigators claim that manu-
acturers are “exempt . . . from any post-marketing surveillance”
1), while in reality, this responsibility is assigned to both the FDA
nd the Federal Trade Commission. Furthermore, the investiga-
ors suggest that manufacturers do not comply with adverse event
eporting law, noting that “between 1990–94, fewer than 10 of
ore than 2,500 reports of adverse effects made to the FDA came
rom herbal product manufacturers” (1). These data, which predate
oth the law requiring the reporting of serious adverse events
2006) and DSHEA (1994), present a skewed view of industry
ompliance.
The investigators suggest a lack of regulation whereby an herbal
ngredient can be introduced to the market without restriction, no
ost-market surveillance is conducted, and herbals present a
isproportional risk to patients. DSHEA, serious adverse event
eporting, and good manufacturing practices for dietary supple-
ents, introduced by the FDA in 2007 but mandated by DSHEA
n 1994, provide a strong and appropriate regulatory framework for
he dietary supplement industry in the U.S. Despite these ad-
ances, potential drug-herb interactions will continue to present
hallenges to practicing clinicians. Thus, to meet patients’ expec-
ations, clinicians need a clear and factual presentation of the
egulatory background of herbal supplement products and a
houghtful evaluation of defined and theoretical contraindications
nd drug interactions affecting patients being treated for cardio-
ascular diseases. This review is a step backward in opening up a
ialogue between clinicians and patients on the topic of herbal
roducts.
M. Hafeez Chaudhry, MD
The Heart Center
610 Carroll Avenue, Suite 300
akoma Park, Maryland 20912
-mail: dchaudhry@aol.com
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e thank Drs. Asher, Dentali, and Chaudhry for their interest in
ur review (1) and for their critical comments. The intent of our
eview, written for cardiologists and other health care providers,
as to provide practical information about issues related to the use
f herbal products in patients with cardiovascular diseases. We
resented the information in easy-to-follow language, minimizing
echnical jargon, to remind busy practicing physicians to ask their
atients about the use of herbal products that could potentially
ncrease adverse drug reactions, including catastrophic events, such
s major bleeds, transplanted organ rejection, predisposition to
ife-threatening arrhythmias, or reductions in the efficacy of
edications used. The review has been received with great
nthusiasm from practicing cardiologists and other health care
roviders but also has generated criticism, mainly from practitio-
ers and from supporters and manufacturers of herbal products.
We thank Dr. Dentali for his comments regarding the impor-
ance of doctor–patient communication and the need for education
bout herbal products, and we appreciate the efforts of the
merican Herbal Products Association to educate the public about
heir use. We were surprised at and disappointed in the comments
egarding our discussion of issues such as a lack of quality control,
dvertising (public misinformation arising from the promotion of
upplements without scientific evidence for their efficacy and
afety), and the regulation of herbal supplements, which have
irect implications for public health. Dr. Dentali’s statement about
he report on colchicine in the placentas of women taking gingko
2) being erroneous is not discredited by the citations provided. In
ur review, we did not raise the issue of whether colchicine can be
ound naturally in ginkgo but in the context of quality control,
ontamination, and adulteration of herbal products (1). In the
eport we cited (2), colchicine was identified by sophisticated
nalytical techniques in placental blood from 5 women who used
erbal supplements but not from 19 nonusers. A significant
mount of colchicine (26  3 g/tablet) was also detected in
ingko biloba purchased from a local market in the Detroit area. In
he Li et al. (3) study, cited by Dr. Dentali, gingko biloba
urchased from pharmacies in Chicago did not reveal any signif-
cant colchicine levels. These findings and other studies indicate an
bsence of colchicine in naturally occurring gingko but do not rule
ut contamination or adulteration, an issue reported with several
erbal products (4–12). The information on the neonatal death is
rom a monograph on ginseng prepared by the Natural Standard
esearch Collaboration (13) and is available at the Medline Plus
ebsite, a service of the U.S. National Library of Medicine and the
ational Institutes of Health. We apologize for the confusion
rom this report that we cited and are thankful to Dr. Dentali for
ointing out the issue of mislabeling (likely adulteration) of
hinese silk vine (Periploca sepium) sold as Siberian ginseng (14).
he effect of black cohosh on cytochrome P450 (CYP) 3A4 has
een demonstrated by several investigators (15–17) and the con-
tituents of the commercially available black cohosh (Cimicifuga
acemosa) that causes the inhibition of human CYP 3A4 identified
15) as triterpene glycosides with weak effect and fukinolic acid and
imicifugic acids A and B as strong inhibitors of 4 CYP isozymes
1A2, 2D6, 2C9, and 3A4) (16). The inhibitory effect of black
ohosh was again confirmed recently by Sevior et al. (17). The
eason for the discrepancy in the reports cited by Dr. Dentali is
nclear. The Dietary Supplement Information Expert Committee
